PLEASE NOTE: Legislative Information cannot perform research, provide legal advice, or interpret Maine law. For legal assistance, please contact a qualified attorney.
An Act To Encourage Alternative Forms of Treatment for Opiate or Opioid Addiction by Prohibiting MaineCare Coverage for Medication-assisted Treatment for Addiction
Be it enacted by the People of the State of Maine as follows:
Sec. 1. 22 MRSA §3174-SS, as enacted by PL 2011, c. 477, Pt. I, §1, is amended by adding at the end a new paragraph to read:
This section is repealed January 1, 2015.
Sec. 2. 22 MRSA §3174-VV, as reallocated by RR 2011, c. 2, §27, is amended by adding at the end a new paragraph to read:
This section is repealed January 1, 2015.
Sec. 3.  22 MRSA §3174-WW  is enacted to read:
§ 3174-WW. Termination of coverage or reimbursement for addiction
 
1.  Termination of coverage for opioid addiction.     Beginning January 1, 2015, the MaineCare program may not provide coverage for buprenorphine and naloxone combination drugs for an individual for the treatment of addiction to opioids.
 
2.  Termination of reimbursement for opiate addiction.     Beginning January 1, 2015, the MaineCare program may not provide reimbursement for methadone for the treatment of addiction to opiates as defined in Title 17-A, section 1101, subsection 7.
 
SUMMARY
Current law limits to 24 months MaineCare coverage or reimbursement for buprenorphine and naloxone combination drugs, also known as Suboxone, for the treatment of addiction to opioids and for methadone for the treatment of addiction to opiates.
This bill, beginning January 1, 2015, prohibits all MaineCare coverage or reimbursement for Suboxone and methadone for treatment of addiction to opioids and opiates, respectively.